Related Experiment Video
Updated: May 22, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
Published on: April 15, 2016
Stabilization of hepatitis C associated collapsing focal segmental glomerulosclerosis with interferon alpha-2a and
Insights
Hepatitis C virus (HCV) infection can cause kidney disease. A case study shows that interferon and ribavirin therapy stabilized HCV-associated collapsing focal segmental glomerulosclerosis (cFSGS) in advanced kidney disease.
Area of Science:
- Nephrology
- Virology
- Immunology
Background:
- Hepatitis C virus (HCV) infection is linked to various glomerular diseases.
- Cryoglobulin-associated membranoproliferative glomerulonephritis Type I is the most common HCV-related kidney disease.
- Focal segmental glomerulosclerosis (FSGS) is rarely reported with HCV, but de novo collapsing FSGS (cFSGS) is noted during interferon treatment.
Observation:
- This report details a specific case of HCV-associated cFSGS.
- The patient presented with advanced kidney disease.
Findings:
- The patient's HCV-associated cFSGS was stabilized.
- Combination therapy with interferon α-2a and ribavirin was utilized.
- This treatment approach proved effective in managing the kidney condition.
Implications:
- Interferon and ribavirin combination therapy can be a viable treatment for HCV-associated cFSGS.
- This case highlights a potential therapeutic strategy for patients with HCV and kidney complications.
- Further research may explore the efficacy of antiviral therapies in managing HCV-related nephropathies.
Abstract:
Hepatitis C virus (HCV) infection is associated with a variety of glomerular diseases, most notably cryoglobulin associated membranoproliferative glomerulonephritis Type I. Focal segmental glomerulosclerosis has only rarely been reported in association with HCV. More striking are multiple reports of de novo collapsing focal segmental glomerulosclerosis (cFSGS) developing during administration of interferon for treatment of HCV. Herein is presented a case of HCV associated cFSGS stabilized with combination therapy of interferon α-2a and ribavirin in a patient with advanced kidney disease.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis
Viral Hepatitis I: Introduction
Cirrhosis II: Pathophysiology
Nephrotic Syndrome II : Assessment and Medical Management
